Abstract:Chimeric antigen receptor T cell (CAR-T) therapy is a late-model of immune cell therapy that has been shown to be effective in refractory/recurrent B-cell leukemia and lymphoma. Compared with the traditional anti-tumor methods, CAR-T cell therapy has the advantages of higher specificity, stronger lethality and longer-lasting efficacy. Although CAR-T cells have made significant progress in the treatment of hematologic malignancies, diverse difficulties remain in the treatment of solid tumors, including immune escape due to tumor antigen heterogeneity, preventing entry or limiting the persistence of CAR-T cells by physical or cytokine barriers and along with other immunosuppressive molecule and cells in the tumor microenvironment (TME). Otherwise, the intracellular signaling of CAR also impact on CAR-T cells persistence. Appropriate modification of intracellular costimulatory molecular signal in the structure of CAR or coexpression of CAR and cytokines can provide a way to enhance CAR-T cells activity. Additionally, CAR-T cells dysfunction due to T cell exhaustion is associated with multi-factors, especially transcription factors, such as c-Jun, NR4A. Engineering CAR-T cells to coexpress or knockout transcription factors in favor of T<sub>CM</sub> memory CAR-T cells differentiation was proved to prolonged the survival of CAR-T cells. Finally, combination of CAR-T cells with oncolytic viruses, nanoparticles or immune checkpoint inhibitors provides an effective measure to improve CAR-T cells function. Here, we discuss all of these advances and challenges and review promising strategies for treating solid tumors. In particular, we also highlight that CAR-T cells have enormous potential to be used in combination with other immunotherapies.

Challenges and strategies associated with CAR-T cell therapy in blood malignancies

Resistance and recurrence of malignancies after CAR-T cell therapy

Relapse after CAR-T Cell Therapy in B-cell Malignancies: Challenges and Future Approaches

CAR-T Cell Therapy in Hematological Malignancies: Current Opportunities and Challenges

Challenges and optimal strategies of CAR T therapy for hematological malignancies.

Fine-Tuning through Generations: Advances in Structure and Production of CAR-T Therapy

Improving the ability of CAR-T cells to hit solid tumors: Challenges and strategies

CAR‐T Therapy in Clinical Practice: Technical Advances and Current Challenges

Advances in CAR-T-cell therapy in T-cell malignancies

Challenges and innovations in CAR-T cell therapy: a comprehensive analysis

Clinical determinants of relapse following CAR-T therapy for hematologic malignancies: Coupling active strategies to overcome therapeutic limitations

[Challenges and strategies for improving efficacy in CAR-T therapy]

Relapse Mechanism and Treatment Strategy After Chimeric Antigen Receptor T-Cell Therapy in Treating B-Cell Hematological Malignancies

Current state of CAR-T therapy for T-cell malignancies

Overcoming the challenges of primary resistance and relapse after CAR-T cell therapy

Advanced Strategies of CAR-T Cell Therapy in Solid Tumors and Hematological Malignancies

Influencing factors and solution strategies of chimeric antigen receptor T-cell therapy (CAR-T) cell immunotherapy

Strategies for Reducing Toxicity and Enhancing Efficacy of Chimeric Antigen Receptor T Cell Therapy in Hematological Malignancies

Mechanisms of resistance to CAR T cell therapies

Metabolic challenges and interventions in CAR T cell therapy

Current progress in CAR-T cell therapy for tumor treatment